Dossier assessment
Inavolisib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Inavolisib (breast cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Inavolisib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with PIK3CA-mutated, oestrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence during or within 12 months of completing adjuvant endocrine treatment
- Female patients < 65 years of age: indication of a minor added benefit
- Female patients ≥ 65 years of age: added benefit not proven
- Male patients: added benefit not proven
Project details
- Project no.
- A25-104
- Commission
- Commission awarded on 11.08.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-104_en